Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03053830
Other study ID # MR0012
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date January 31, 2017
Est. completion date September 26, 2018

Study information

Verified date September 2023
Source VA Connecticut Healthcare System
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Medically healthy Veterans ages 21-75 that have been diagnosed with Depression will get up to 6 treatments of Ketamine infusions, weekly. After treatment is completed, follow up will occur at 1 month, 3 months, and 6 months after completion of infusions to evaluate the longer term effects of ketamine.


Description:

A total of 25 depressed subjects between the ages of 21-75 who have current major depressive disorder without psychotic features by DSM-5 will be recruited. Subjects will be accepted into the protocol after an opportunity to review and provide voluntary written informed consent and completion of a comprehensive medical and psychiatric history, physical examination, mental status examination, and routine laboratory assessments. Patients will be recruited in outpatient settings to the Refractory Depression Clinic. Providers or Refractory Depression consult team will be informed if the patient may be eligible for participation in the ketamine protocol. Subjects must have established care in the VA Connecticut Healthcare System. If the Veteran is interested, a screening visit for further evaluation for the ketamine protocol will be scheduled. Veterans will receive up to 6 infusions for ketamine weekly, per PI discretion. The primary goal of this proposal is to test the effectiveness of repeated ketamine treatment (0.5 mg/kg; once or twice a week for up to 6 weeks; up to a total of 6 ketamine infusions). An open-label trial will be conducted that will include up to 25 Veterans with MDD with a follow-up of 6 months. This open-label trial will allow us to examine the safety and tolerability of the ketamine treatment in this population and the long-term effects. All patients will receive usual standard care during this trial.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date September 26, 2018
Est. primary completion date September 26, 2018
Accepts healthy volunteers No
Gender All
Age group 21 Years to 75 Years
Eligibility Inclusion Criteria: 1. Male or female, 21-75 years old 2. Current major depressive disorder without psychotic features by DSM-5 3. Montgomery-Åsberg Depression Rating Scale (MADRS) = 20 4. Able to provide written informed consent Exclusion Criteria: 1. Current or past history of psychotic features or psychotic disorder 2. Current or past history of delirium or dementia 3. Current uncontrolled hypertension (systolic BP > 170 mm Hg or diastolic BP > 100 mm Hg) 4. Unstable medical condition or allergy to ketamine or lorazepam---clinically determined by a physician 5. Pregnant or nursing women, positive pregnancy test, or inadequate birth control methods in women of childbearing potential 6. Positive opioid or illicit drug screen test (except marijuana)

Study Design


Intervention

Drug:
Ketamine
0.5mg/kg ketamine in normal saline. Infusion will be delivered during a 40 minute interval

Locations

Country Name City State
United States VA Healthcare System West Haven Connecticut

Sponsors (1)

Lead Sponsor Collaborator
VA Connecticut Healthcare System

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Montgomery-Asberg Depression Rating Scale (MADRS) MADRS is a standardized instrument to ascertain depressed mood and neurovegetative signs and symptoms of a major depressive episode. Baseline, 40 mins after infusion, 140 mins after infusion, 240 mins after infusion
Primary Change in Quick Inventory of Depressive Symptomatology-Self Report (QUIDS-SR) A patient rated depression instrument Baseline, 40 mins after infusion, 80 mins after infusion, 110 mins after infusion, 240 mins after infusion
Primary Change in Hamilton Anxiety Rating Scale (HAM-A) Standardized instrument to evaluate anxiety severity Frame: Baseline, 40 mins after infusion,140 mins after infusion, 240 mins after infusion
Primary Clinical Global Impression Scale Widely used instrument which asses overall severity of illness on a 1-7 point scale, with 1 indicating, not at all ill and 7 indicating among the most extremely ill patients Baseline
Primary Change in Brief Psychotic Rating Scale (BPRS) The BPRS is a standardized instrument that contains scales assessing psychotic symptoms including positive and negative symptoms, activation and emotional distress. Baseline, 40 mins after infusion, 80 mins after infusion, 110 mins after infusion, 140 mins after infusion, 240 mins after infusion
Primary Change in Clinician-Administered Dissociative States Scale (CADSS) The CADSS has self and interviewer-administered items including 5 subscales, generated a priori, evaluating dissociation including altered environmental perception, time perception, spatial/body perception, derealization and memory impairment. Baseline, 40 mins after infusion, 80 mins after infusion, 110 mins after infusion, 140 mins after infusion, 240 mins after infusion
Primary Change in Visual Analog Scale (VAS) of Mood States The VAS includes scales for anxiety, drowsiness, high irritability, anger and sadness. The scales are 100 mm lines marked by subjects at a point corresponding to the apparent intensity of the feeling state (0 = none, to 100 = most ever). Baseline, 40 mins after infusion, 80 mins after infusion, 110 mins after infusion, 140 mins after infusion, 240 mins after infusion
Primary Time Line Follow Back (TLFB) The TLFB is a standardized measure utilized for collecting information on daily alcohol use as well as other substance use. Baseline
Primary Columbia-Suicide Severity Rating Scale (C-SSRS) The C-SSRS has both lifetime/recent and since last visit versions. The "Lifetime/Recent" version gathers information on lifetime history of suicidality and recent suicidal ideation/self-injurious behavior. The "Since Last Visit" version of the C-SSRS asks about any suicidal thoughts or behaviors the subject has exhibited since the last time administered the C-SSRS. Baseline
Primary Quality of life enjoyment and satisfaction survey (Q-LES-Q) The Q-LES-Q is a self-report measure of quality of life. Baseline
Primary Cognition A standard computerized battery will be done to assess cognitive ability post treatment of ketamine. The battery will include a wide range on cognitive tasks including but not
limited to attention, learning, and working memory. While it is know ketamine causes acute cognitive effects, the longer-term effects of ketamine are not known. When the cognitive battery is being conducted on test days it will be done at the end of the test day, to eliminate the confounding effects of acute treatment of ketamine..
140 mins after infusion
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4